Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin and Penpulimab Neoadjuvant Therapy for Bladder Urothelial Carcinoma
NCT05488353Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 4 trial of disitamab vedotin, penpulimab in bladder urothelial carcinoma, sponsored by Sun Yat-sen Memorial Hospital. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
disitamab vedotinpenpulimab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT05488353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488353.